Thinking beyond surgery in the management of renal cell carcinoma: The risk to die from renal cell carcinoma and competing risks of death

World Journal of Urology

Volumn 32, Issue 3, 2014, Pages 607-613

  Chen, David Y T ^a   Uzzo, Robert G ^a   Viterbo, Rosalia ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

Comorbidity; Medical decision making; Nomogram; Prognostic measurement; Renal cell carcinoma; SEER

Indexed keywords

CARCINOMA, RENAL CELL; CAUSE OF DEATH; COMORBIDITY; DISEASE MANAGEMENT; HEALTH; HUMAN; KIDNEY NEOPLASMS; NEPHRECTOMY; PROCEDURES; PROGNOSIS; RISK ASSESSMENT; SURVIVAL RATE;

CARCINOMA, RENAL CELL; CAUSE OF DEATH; COMORBIDITY; DISEASE MANAGEMENT; GLOBAL HEALTH; HUMANS; KIDNEY NEOPLASMS; NEPHRECTOMY; PROGNOSIS; RISK ASSESSMENT; SURVIVAL RATE;

EID: 84901479062     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-014-1285-6     Document Type: Article

References (31)

1. Chow WH, Devesa SS, Warren JL, Fraumeni JF Jr (1999) Rising incidence of renal cell cancer in the United States. JAMA 281(17): 1628-1631.
2. Kane CJ, Mallin K, Ritchey J, Cooperberg MR, Carroll PR (2008) Renal cell cancer stage migration: analysis of the national cancer data base. Cancer 113(1): 78-83.
3. Parsons JK, Schoenberg MS, Carter HB (2001) Incidental renal tumors: casting doubt on the efficacy of early intervention. Urology 57(6): 1013-1015.
4. Russo P, Jang TL, Pettus JA et al (2008) Survival rates after resection for localized kidney cancer: 1989 to 2004. Cancer 113(1): 84-96.
5. Gill IS, Kavoussi LR, Lane BR et al (2007) Comparison of 1, 800 laparoscopic and open partial nephrectomies for single renal tumors. J Urol 178(1): 41-46.
6. Hollingsworth JM, Miller DC, Daignault S, Hollenbeck BK (2006) Rising incidence of small renal masses: a need to reassess treatment effect. J Natl Cancer Inst 98(18): 1331-1334.
7. Hollingsworth JM, Miller DC, Daignault S, Hollenbeck BK (2007) Five-year survival after surgical treatment for kidney cancer: a population-based competing risk analysis. Cancer 109(9): 1763-1768.
8. Uijen AA, van de Lisdonk EH (2008) Multimorbidity in primary care: prevalence and trend over the last 20 years. Eur J Gen Pract 14(Suppl 1): 28-32.
9. Partnership JR. Chronic conditions: making the case for ongoing care. http://www. partnershipforsolutions. org/DMS.
10. Kassouf W, Aprikian AG, Laplante M, Tanguay S (2004) Natural history of renal masses followed expectantly. J Urol 171(1): 111-113 (discussion 113).
11. Volpe A, Panzarella T, Rendon RA, Haider MA, Kondylis FI, Jewett MA (2004) The natural history of incidentally detected small renal masses. Cancer 100(4): 738-745.
12. Chawla SN, Crispen PL, Hanlon AL, Greenberg RE, Chen DY, Uzzo RG (2006) The natural history of observed enhancing renal masses: meta-analysis and review of the world literature. J Urol 175(2): 425-431.
13. Crispen PL, Viterbo R, Boorjian SA, Greenberg RE, Chen DY, Uzzo RG (2009) Natural history, growth kinetics, and outcomes of untreated clinically localized renal tumors under active surveillance. Cancer 115(13): 2844-2852.
14. Smaldone MC, Kutikov A, Egleston BL et al (2012) Small renal masses progressing to metastases under active surveillance: a systematic review and pooled analysis. Cancer 118(4): 997-1006.
15. Smaldone MC, Uzzo RG (2011) Active surveillance: a potential strategy for select patients with small renal masses. Future Oncol 7(10): 1133-1147.
16. Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5): 373-383.
17. Rochon PA, Katz JN, Morrow LA et al (1996) Comorbid illness is associated with survival and length of hospital stay in patients with chronic disability. A prospective comparison of three comorbidity indices. Med Care 34(11): 1093-1101.
18. D'Hoore W, Sicotte C, Tilquin C (1993) Risk adjustment in outcome assessment: the Charlson comorbidity index. Methods Inf Med 32(5): 382-387.
19. Pompei P, Charlson ME, Douglas RG Jr (1988) Clinical assessments as predictors of one year survival after hospitalization: implications for prognostic stratification. J Clin Epidemiol 41(3): 275-284.
20. Sarfati D (2012) Review of methods used to measure comorbidity in cancer populations: no gold standard exists. J Clin Epidemiol 65(9): 924-933.
21. Lund L, Jacobsen J, Norgaard M et al (2006) The prognostic impact of comorbidities on renal cancer, 1995 to 2006: a Danish population based study. J Urol 182(1): 35-40 (discussion 40).
22. Santos Arrontes D, Fernandez Acenero MJ, Garcia Gonzalez JI, Martin Munoz M, Paniagua Andres P (2008) Survival analysis of clear cell renal carcinoma according to the Charlson comorbidity index. J Urol 179(3): 857-861.
23. Gettman MT, Boelter CW, Cheville JC, Zincke H, Bryant SC, Blute ML (2003) Charlson co-morbidity index as a predictor of outcome after surgery for renal cell carcinoma with renal vein, vena cava or right atrium extension. J Urol 169(4): 1282-1286.
24. Berger DA, Megwalu II, Vlahiotis A et al (2008) Impact of comorbidity on overall survival in patients surgically treated for renal cell carcinoma. Urology 72(2): 359-363.
25. Piccirillo JF, Tierney RM, Costas I, Grove L, Spitznagel EL Jr (2004) Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA 291(20): 2441-2447.
26. O'Connor KM, Davis N, Lennon GM, Quinlan DM, Mulvin DW (2009) Can we avoid surgery in elderly patients with renal masses by using the Charlson comorbidity index? BJU Int 103(11): 1492-1495.
27. Campbell SC, Novick AC, Belldegrun A et al (2009) Guideline for management of the clinical T1 renal mass. J Urol 182(4): 1271-1279.
28. Ljungberg B, Cowan NC, Hanbury DC et al (2010) EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol 58(3): 398-406.
29. Kutikov A, Egleston BL, Wong YN, Uzzo RG (2010) Evaluating overall survival and competing risks of death in patients with localized renal cell carcinoma using a comprehensive nomogram. J Clin Oncol 28(2): 311-317.
30. Lughezzani G, Sun M, Budaus L, Thuret R, Perrotte P, Karakiewicz PI (2010) Population-based external validation of a competing-risks nomogram for patients with localized renal cell carcinoma. J Clin Oncol 28(18): e299-e300 (author reply e301).
31. Kutikov A, Egleston BL, Canter D, Smaldone MC, Wong YN, Uzzo RG (2012) Competing risks of death in patients with localized renal cell carcinoma: a comorbidity based model. J Urol 188(6): 2077-2083.